Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
September 2023
Chan Li, Jiping Zhang, Hanhe Liu et al.
Depression is a multifactorial syndrome with a variety of underlying pathological mechanisms. While ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, exhibits a rapid antidepressant action in the central never system (CNS), the potential addiction and psychotomimetic adverse effects of ketamine limit its chronic use in clinical practice. Therefore, it is necessary to discover an...
The Brown University Psychopharmacology Update
September 1, 2023
A large‐scale open‐label trial conducted at electroconvulsive therapy (ECT) clinics has found that twice‐weekly dosing of ketamine was noninferior to three sessions a week of ECT in patients with treatment‐resistant major depression. Relapse rates during a 6‐month follow‐up period after the initial 3‐week treatment period were higher among patients receiving ECT than patients receiving...
International Clinical Psychopharmacology
September 1, 2023
Nicolas Garel, Michka Nazon, Kamran Naghi et al.
7 citations
Medical Aid in Dying (MAiD) is the act of a healthcare provider ending a patient's life, at their request, due to unbearable suffering from a grievous and incurable disease. Access to MAiD has expanded in the last decade and, more recently, it has been made available for psychiatric illnesses in a few countries. Recent studies have found that such psychiatric requests are rapidly increasing and...
Pharmacology, Biochemistry, and Behavior
September 1, 2023
Yixue Qin, Haoxuan Li, Yuqi Zhang et al.
6 citations
Ketamine has been increasingly used as a rapid-onset antidepressant in specific clinical settings. However, as a psychedelic reagent, the potential of physical and psychological dependence limits its clinical use. Here, we added retigabine, a KCNQ channel opener, as an adjunctive treatment to observe its effect on ketamine's antidepressant property in a forced swim test in both male and female...
Journal of Exploratory Research in Pharmacology
August 28, 2023
Ryan Dao, Amit Aggarwal
2 citations
Major depressive disorder (MDD) continues to be a prevalent disease worldwide. While selective serotonin reuptake inhibitors and other medications continue to be prescribed, further research has been conducted toward other treatment modalities. Within the past decade, ketamine, an N-methyl-d-aspartate receptor antagonist, has been extensively studied as a new treatment for MDD. Recent studies...
Psychiatry Research Case Reports
August 20, 2023
Brian S. Barnett, Amit Anand
Though usually mild, neuropsychiatric side effects of intravenous ketamine for depression occasionally result in treatment discontinuation. Two small clinical trials of healthy subjects have indicated that lamotrigine pre-treatment may attenuate these side effects, though two other trials, one in patients with unipolar depression and one in healthy male volunteers, did not support these...
Trials
August 19, 2023
Kaili Yu, Zhenguo Song, Bowen Zhang et al.
Pancreatoduodenectomy (PD) is traumatic, difficult to perform, and has a high incidence of postoperative complications and perioperative mortality. Postoperative complications and pain occur frequently and seriously affect the psychological status of patients. Esketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has analgesic and antidepressant effects. In this study, we aim to...
Depression and Anxiety
August 19, 2023
Anna J. Harvey, Stevan Nikolin, Nicholas Chand et al.
4 citations
Ketamine has recently emerged as a highly effective new treatment for people with treatment-resistant depression with rapid antidepressant effects. However, these effects are often short lasting, and the potential cognitive mechanisms underlying the therapeutic effects, such as effects on emotional processing bias, remain poorly understood. In the present study, we explored potential changes in...
Trials
August 13, 2023
Irina Falkenberg, Florian Bitsch, Wei Liu et al.
4 citations
Abstract Background Major depressive disorder (MDD) is a highly prevalent (8–15%), severely disabling disorder and is associated with enormous socioeconomic impact. Antidepressant medication for the treatment of MDD has proven effective in RCTs; however, placebo response is also substantial. Given the potential benefits of modulating the placebo response in patient care and pharmacological...
BMC Psychiatry
August 11, 2023
Abstract: Background: Esketamine (ESK) nasal spray, taken with oral antidepressant therapy, is approved for the treatment of depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. In pooled analyses of two pivotal phase 3 studies, ASPIRE I and II, remission rates were consistently higher among patients with MDD with active suicidality who...